Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2017 02:00 ET | Source: Verona Pharma plc

Total Voting Rights

UK DISCLOSURE, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Total Voting Rights...
September 27, 2017 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients

LONDON, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
September 19, 2017 07:53 ET | Source: Verona Pharma plc

Issue of Shares

UK DISCLOSURE, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Issue of Shares...
September 07, 2017 02:00 ET | Source: Verona Pharma plc

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)

Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium Demonstrated statistical significance across all...
September 01, 2017 02:00 ET | Source: Verona Pharma plc

Verona Pharma Appoints Stifel as Nominated Adviser

UK DISCLOSURE, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma Appoints Stifel as Nominated Adviser ...
August 21, 2017 05:33 ET | Source: Verona Pharma plc

PDMR Dealing

LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
August 08, 2017 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update

Completed US IPO Continues to advance lead candidate RPL554 with four clinical trials commenced LONDON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”...
August 02, 2017 11:00 ET | Source: Verona Pharma plc

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update

LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
August 01, 2017 07:00 ET | Source: Verona Pharma plc

Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference

LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
July 26, 2017 02:00 ET | Source: Verona Pharma plc

Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...